Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Thermo Fisher Scientific's average EPS without NRI Growth Rate was 8.90% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -0.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 0.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 13.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Thermo Fisher Scientific was 55.00% per year. The lowest was -65.90% per year. And the median was 12.25% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thermo Fisher Scientific 3-Year EPS without NRI Growth Rate Related Terms
BSP:TMOS34 vs DHR, IDXX, A: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's 3-Year EPS without NRI Growth Rate falls into.
Thermo Fisher Scientific 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -0.50% mean?
Thermo Fisher Scientific (BSP:TMOS34) has a 3-Year EPS without NRI Growth Rate of -0.50% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Thermo Fisher Scientific and its competitors. According to the industry distribution chart, Thermo Fisher Scientific ranks #103 out of 158 companies in the Medical Diagnostics & Research industry, placing it in the top 65.2%.
Is Thermo Fisher Scientific's 3-Year EPS without NRI Growth Rate too high?
Thermo Fisher Scientific's current 3-Year EPS without NRI Growth Rate is -0.50%. Based on the distribution chart, Thermo Fisher Scientific ranks #103 out of 158 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Thermo Fisher Scientific has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's 3-Year EPS without NRI Growth Rate compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #103 out of 158 companies for 3-Year EPS without NRI Growth Rate. This places Thermo Fisher Scientific in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.75, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current 3-Year EPS without NRI Growth Rate is -0.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Fairly Valued. The stock's GF Value™ is R$63.70, compared to a current price of R$65.72 — trading 3.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -0.50%. Thermo Fisher Scientific's overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current 3-Year EPS without NRI Growth Rate is -0.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be overvalued.
The current stock price of R$65.72 is trading 3.2% above its estimated GF Value™ of R$63.70.
GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.
Key valuation signals for BSP:TMOS34:
3-Year EPS without NRI Growth Rate: -0.50%
GF Value™: R$63.70 vs. price of R$65.72 (3.2% above fair value)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
75GF Score
Get the complete analysis for BSP:TMOS34
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
